Manipal Payment and Identity Solutions made a weak stock market debut on Thursday, September 17, 2026, with its shares listing at a 2.65% discount on the NSE. The stock opened at ₹330 apiece on the NSE against its IPO issue price of ₹339 per share. On the BSE, the shares debuted at ₹332 per share, representing a 2.06% discount over the issue price.
The company’s ₹805.00 crore IPO was open for subscription from September 9 to September 11, 2026, and witnessed muted investor interest. The issue was subscribed 1.42 times by the end of the bidding period.
Explore other Upcoming IPOs on BSE and NSE.
[September 11, 2026, 7:00 P.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
1.26x |
|
Non-Institutional Investors (NIIs) |
1.22x |
|
Retail Individual Investors (RIIs) |
2.19x |
|
Total |
1.42x |
The company intends to utilise the net proceeds from the fresh issue towards:
Incorporated in 2008 and part of the Manipal Group, Manipal Payment and Identity Solutions Limited provides technology-enabled solutions across payments, identification, secure printing, smart tagging, and IoT. It serves banks, fintech companies, NBFCs, and government institutions in India and overseas. Its offerings include payment cards, cheque solutions, NFC and QR-based payment products, wearables, identity documents, secure printing, RFID tracking, tamper-evident packaging, and anti-counterfeiting solutions.
In FY2026, the company accounted for an estimated 36.4% of India's credit card issuance and 30.9% of debit card issuance. It billed 13.54 million credit cards and 72.66 million debit cards during the year, reflecting its significant presence in India's payment card issuance market.
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
1,326.75 |
1,256.07 |
1,247.52 |
|
EBITDA |
455.83 |
408.76 |
355.57 |
|
Profit After Tax (PAT) |
253.46 |
282.21 |
249.16 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here